S
Salubris Biotherapeutics
Developing innovative and transformative therapeutic molecules to provide clinically meaningful improvements in disease burden and quality of life to patients with significant medical needs
About Salubris Biotherapeutics
Salubris Biotherapeutics, Inc. (SalubrisBio) is a clinical-stage biotechnology company focused on the discovery and development of novel antibody and protein-based therapeutics. The company targets significant medical needs in the areas of cardiovascular disease, oncology, and neurodegenerative diseases, which are among the leading causes of death globally. SalubrisBio operates in the biopharmaceutical market, serving patients with severe and life-threatening conditions. The business model revolves around the research, development, and clinical testing of innovative therapeutic molecules, aiming to bring these therapies to market through regulatory approval and commercialization. Revenue is generated through partnerships, licensing agreements, and eventual product sales once therapies receive market approval.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2016
- Headquarters
- Gaithersburg, United States
- Employees
- 40
- Open positions
- 1
- Dealroom signal
- 81.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Apr 2024 | $35M | $140M | Undisclosed | ↗ |
| EARLY VC✓Equity / VC | Mar 2023 | $35M | $140M | Shenzhen Salubris Pharmaceuticals | ↗ |
Growth signals
Latest recorded traffic for Salubris Biotherapeutics is 100 monthly website visits, down 89.4% over the last three months. Salubris Biotherapeutics's team grew 25% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Shenzhen Salubris Pharmaceuticals
Other known investors2 additional known investors
- CCCarlyle Cardinal Ireland - CCI
The Carlyle Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Salubris Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Salubris Biotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.